Last €39.81 EUR
Change Today +1.19 / 3.07%
Volume 148.8K
IPN On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
OTC US
Stuttgart
As of 11:35 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

65, quai Georges Gorse

Cedex

Boulogne-Billancourt, 92650

France

Phone: 33 1 58 33 50 00

Fax: 33 1 58 33 50 01

Ipsen S.A. engages in the research, development, manufacture, and sale of pharmaceutical products worldwide. The company’s product portfolio includes pharmaceutical products marketed to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology), which are its primary areas of development. It also markets products in other therapeutic areas in which it boasts longstanding expertise (gastroenterology, cardiovascular, and cognitive disorders). SPECIALIST CARE Oncology Decapeptyl is a peptide formulation for injection used to treat advanced prostate cancer. Endocrinology Somatuline and Somatuline Autogel, are sustained release formulations for injection of a somatostatin analogue peptide, used primarily in the treatment of acromegaly. NutropinAq is a liquid formulation for daily use of recombinant human growth hormone used primarily in the treatment of growth failure in children and growth hormone deficiency in adults. Neurology Dysport is a botulinum neurotoxin type A complex, used notably to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. Apokyn is used for the treatment of off episodes (reemergence of Parkinson’s disease symptoms) associated with advanced Parkinson’s disease, namely when the therapeutic effects of the conventional treatment (L-Dopa) diminish. PRIMARY CARE Gastroenterology (18.8% of 2008 consolidated sales) Smecta is a natural clay-based drug used in the treatment of both chronic and acute diarrhoea. Forlax is a drug based on a linear polyethylene glycol polymer used in the treatment of constipation. Cognitive Disorders Tanakan is an oral formulation of EGb 761, extracted from the leaves of the Ginkgo biloba tree, used principally in the treatment of age-related cognitive disorders. Cardiovascular Nisis and Nisisco are oral formulations notably containing valsartan, used in the treatment of arterial hypertension. Ginkor Fort is an oral formulation containing three active substances including a standardised extract from the leaves of the Ginkgo biloba tree used in the treatment of venous insufficiency of the lower limbs and acute haemorrhoid episodes. Acquisitions In 2008, the company completed the acquisition of the rights to Apokyn, and Vernalis’ U.S. Commercial Operations. In 2008, the company acquired its U.S. subsidiary Vernalis Pharmaceuticals, Inc. and the rights to develop and market Apokyn in the U.S. History Ipsen S.A. was founded in 1929.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPN:FP €39.81 EUR +1.19

IPN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €11.42 EUR -0.10
Meda AB kr101.50 SEK +2.40
Orion OYJ €30.00 EUR +0.84
Procter & Gamble Hygiene & Health Care Ltd 4,863 INR -24.15
Recordati SpA €12.82 EUR -0.21
View Industry Companies
 

Industry Analysis

IPN

Industry Average

Valuation IPN Industry Range
Price/Earnings 19.8x
Price/Sales 2.4x
Price/Book 3.1x
Price/Cash Flow 18.8x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IPSEN, please visit www.ipsen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.